FDA Classifies Prolia(TM) (Denosumab) Complete Response Submission and Targets Action Date
- Details
- Category: Amgen

Lilly, Merck, And Pfizer Announce the Formation of the Asian Cancer Research Group, Inc.
- Details
- Category: Pfizer

Novartis receives FDA approval of Menveo®
- Details
- Category: Novartis

US FDA approves Rituxan/MabThera for the most common type of adult leukemia
- Details
- Category: Roche

GSK rejects conclusions of Senate Committee on Finance Staff Report on Avandia
- Details
- Category: GlaxoSmithKline

GSK rejects conclusions reported in The New York Times story on Avandia
- Details
- Category: GlaxoSmithKline

GlaxoSmithKline and XenoPort receive FDA Complete Response letter for Horizantâ¢
- Details
- Category: GlaxoSmithKline

More Pharma News ...
- Genzyme Reports Financial Results for Fourth Quarter of 2009 and Full Year
- AstraZeneca and Rigel Pharmaceuticals Sign Worldwide License Agreement
- Abbott Completes Acquisition of Solvay Pharmaceuticals
- Abbott Receives U.S. FDA Approval for Heat-Stable Norvir® (ritonavir) Tablets
- Roche study drug may offer valuable new treatment option for patients with type 2 diabetes
- Lilly's Online, Interactive Health Education Program Receives Two Web Awards
- Novartis gains exclusive rights to Debio 025